Amphastar Pharmaceuticals Inc. keeps its eye on the goal of making its asthma inhaler Primatene Mist available OTC again as a second complete response letter from FDA pushes the finish line back further.
Amphastar on Dec. 27 announced it received a CRL on the firm’s new drug application for making Primatene Mist available...



